Reticulocalbin-2 (RCN2) as a Context-Dependent CREC-Family Modulator: Gene Expression and Regulation, Molecular Biology, Disease Relevance, and Translational Challenges.
- 1Department of Biology, Faculty of Science, Al-Baha University, Al-Baha 65779, Saudi Arabia.
Abstract
Reticulocalbin-2 (RCN2), encoded by the human RCN2 gene (HGNC:9935) and historically identified as E6-binding protein, is a CREC-family EF-hand Ca²⁺-binding protein. Although first characterized as an endoplasmic reticulum (ER)-associated protein, current evidence extends RCN2 biology to splice-variant and localization complexity, protein interactions, regulatory and signaling networks, extracellular activity, cancer, non-malignant disease, and the RCN2-derived hormone Raptin. This review synthesizes the fragmented and methodologically uneven RCN2 literature within an evidence-stratified framework. Mechanistic evidence, including direct biochemical assays and RCN2-directed functional studies, supports selected interaction and signaling relationships, whereas omics, database-derived and single-context observations remain hypothesis-generating. Across disease settings, RCN2 is best interpreted as a context-dependent modulator rather than a uniform oncogenic driver, validated biomarker or established therapeutic target. Translational progress will require molecular-form-specific assays, disease-specific validation and clinically grounded models.
Related
- Dynamic three-dimensional chromatin remodeling in lung disease: mechanistic principles, pathogenic regulatory networks, and translational challenges
- HDAC inhibitors in cancer therapy: sensitization mechanisms, combination strategies, and translational challenges
- Multipath interaction network of annexin A2: multifaceted regulation and translational perspectives in neurological diseases
- Natural polysaccharides as modulators of mitochondrial homeostasis: structural determinants, pharmacological mechanisms, and translational challenges
- Divergent roles of H3K18 lactylation in human diseases: metabolic-epigenetic circuits and translational challenges
BibTeX
@article{alghamdi2026reticulocalbin2,
title = {{Reticulocalbin-2 (RCN2) as a Context-Dependent CREC-Family Modulator: Gene Expression and Regulation, Molecular Biology, Disease Relevance, and Translational Challenges.}},
author = {Abdullah A A Alghamdi},
journal = {Genes},
year = {2026},
month = oct,
doi = {10.3390/genes17101226},
url = {https://europepmc.org/article/MED/42938341},
note = {CC BY},
}
RIS
TY - JOUR
TI - Reticulocalbin-2 (RCN2) as a Context-Dependent CREC-Family Modulator: Gene Expression and Regulation, Molecular Biology, Disease Relevance, and Translational Challenges.
AU - Abdullah A A Alghamdi
PY - 2026
DA - 2026/10/02
JO - Genes
DO - 10.3390/genes17101226
UR - https://europepmc.org/article/MED/42938341
AB - Reticulocalbin-2 (RCN2), encoded by the human RCN2 gene (HGNC:9935) and historically identified as E6-binding protein, is a CREC-family EF-hand Ca²⁺-binding protein. Although first characterized as an endoplasmic reticulum (ER)-associated protein, current evidence extends RCN2 biology to splice-variant and localization complexity, protein interactions, regulatory and signaling networks, extracellular activity, cancer, non-malignant disease, and the RCN2-derived hormone Raptin. This review synthesizes the fragmented and methodologically uneven RCN2 literature within an evidence-stratified framework. Mechanistic evidence, including direct biochemical assays and RCN2-directed functional studies, supports selected interaction and signaling relationships, whereas omics, database-derived and single-context observations remain hypothesis-generating. Across disease settings, RCN2 is best interpreted as a context-dependent modulator rather than a uniform oncogenic driver, validated biomarker or established therapeutic target. Translational progress will require molecular-form-specific assays, disease-specific validation and clinically grounded models.
SN - 2073-4425
ER -